Lipsker D.- Growth rate, early detection and prevention of melanoma. Melanoma epidemiology revisited and future challenges. Arch Dermatol, 2006, 142, 1638-1640.
Liu W, Dowling JP, Murray WK, et al.- Rate of growth in melanomas : characteristics and associations of rapidly growing melanomas. Arch Dermatol, 2006, 142, 1551-1558.
Lipsker D, Engel F, Cribier B, et al.- Trends in melanoma epidemiology suggest three different types of melanoma. Br J Dermatol, 2007, 157, 338-343. (Pubitemid 47083865)
Piérard GE, Quatresooz P, Rorive A, et al.- Le mélanome cutané : innovations conceptuelles et thérapeutiques, fruit de la recherche translationnelle. Rev Med Liège, 2008, 63, 579-584.
Zalaudek I, Marghoob AA, Scope A, et al.- Three roots of melanoma. Arch Dermatol, 2008, 44, 1375-1378.
Piérard-Franchimont C, Arrese JE, Quatresooz P, et al.- Mini-mélanome papulo-achromique de croissance rapide. Dermatol Actual, 2009, 114, 8-10.
Quatresooz P, Arrese JE, Piérard-Franchimont C, Piérard GE.- Immunohistochemical aid at risk stratification of melanocytic neoplasms. Int J Oncol, 2004, 24, 211-216.
Piérard GE, Piérard-Franchimont C, Groupe Mosan d'Etude des Tumeurs Pigmentaires.- Malignant melanoma and its growth fraction. Dans : Trends in Dermatology Research Pub. Novascience, sous presse.
Quatresooz P, Piérard GE, Piérard-Franchimont C, et al.- Molecular pathways supporting the proliferation staging of malignant melanoma. Int J Mol Med, 2009, 24, 295-301.
Piérard GE, Piérard-Franchimont C, Henry C, Lapière M.- The proliferative activity of cells of malignant melanomas. Am J Dermatopathol, 1984, 6, S317-S324.
Piérard GE, Piérard-Franchimont C.- Stochastic relationship between the growth fraction and vascularity of thin malignant melanomas. Eur J Cancer, 1997, 33, 1888-1892.
Piérard-Franchimont C, Henry F, Heymans O, Piérard GE.- Vascular retardation in dormant growth-stunted malignant melanomas. Int J Mol Med, 1999, 4, 403-406.
Quatresooz P, Hustinx R, Piérard-Franchimont C, Piérard GE.- Le mélanome cutané dans une perspective liégeoise. Actualisation de son épidémiologie et avancées diagnostiques. Rev Med Liège, 2007, 62, S52-S55.
Quatresooz P, Piérard-Franchimont C, Piérard GE, et al.- Molecular histology on the diagnostic cutting edge between malignant melanomas and melanocytomas. Oncol Rep, sous presse.
Piérard-Franchimont C, Piérard GE.- Comment j'explore... un patient atteint de mélanome : actualisation d'un algorithme. Rev Med Liège, 2006, 61, 837-842.
Smoller BR.- Histologic criteria for diagnosing primary cutaneous malignant melanoma. Modern Pathol, 2006, 19, 34-40.
Heymans O, Blacher S, Brouers F, Piérard GE.- Fractal quantification of the microvasculature heterogeneity in cutaneous melanoma. Dermatology, 1999, 198, 212-217.
Quatresooz P, Petit L, Uhoda I, et al.- Space-time clustering and seasonality in diagnosing skin cancers in Wallonia (South East Belgium). Dermatology, 2008, 217, 48-51.
Tejera-Vaquerizo A, Mendiola-Fernandez M, Fernandez- Orland A, Herrera-Ceballos E.- Thick melanoma : the problem continues. J Eur Acad Dermatol Venereol, 2008, 22, 575-579.
Klein WM, Wu BP, Zhao S, et al.- Increased expression of stem cell markers in malignant melanoma. Modern Pathol, 2007, 20, 102-107.
Monzani E, Facchetti F, Galmozzi E, et al.- Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer, 2007, 43, 935-946. (Pubitemid 46366698)
Rappa G, Fodstad O, Lorico A.- The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells, 2008, 26, 3008-3017.
Schatton T, Murphy GF, Frank NY, et al.- Identification of cells initiating human melanomas. Nature, 2008, 451, 345-349.
